| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Other income, net | 72,635 | 94,742 | ||
| Loss before income taxes | -3,037,420 | -3,716,157 | ||
| Provision for income taxes | - | 0 | ||
| Net loss | -3,037,420 | -3,716,157 | ||
| Foreign currency translation | 18,301 | 5,631 | ||
| Comprehensive loss | -3,019,119 | -3,710,526 | ||
| Basic loss per share (in dollars per share) | -0.41 | -0.66 | ||
| Diluted loss per share (in dollars per share) | -0.41 | -0.66 | ||
| Weighted-average common shares outstanding, basic (in shares) | 7,443,577 | 5,641,251 | ||
| Weighted-average common shares outstanding, diluted (in shares) | 7,443,577 | 5,641,251 | ||
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)